READ-ONLY DIGITIZATION RESULT
Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial.
JAMA Oncol · 2026-Feb-01 · PMID 41343176
Panel A质量警告待 EXE 对齐验证
Disease-Free Survival
Figure 3. Disease-Free Survival (DFS) by Celecoxib vs. Placebo and Circulating Tumor DNA (ctDNA) Status Among Select Subgroups of Interest. [A] Non-MSI-High [B] MSI-High [C] PIK3CA Wildtype [D] PIK3CA Mutant Disease free survival, stratified by assigned oral agent (celecoxib or placebo) and postoperative ctDNA status in 2×2 fashion. Shown are subgroups of patients with A: non-microsatellite instability high tumors (non-MSI-High), B: microsatellite instability high tumors (MSI-High), C: PIK3CA wildtype tumors, and D: PIK3CA mutant tumors. Data cutoff was 6 years after time of randomization.
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
| Curve | 序号 | X (norm) | Y (norm) | X (real) | Y (real) | X (pixel) | Y (pixel) |
|---|---|---|---|---|---|---|---|
| 1 | 1 | 0.0000 | 0.9356 | 0.0000 | 84.2000 | 132 | 54 |
| 1 | 2 | 0.1352 | 0.9356 | 0.8066 | 84.2000 | 230 | 54 |
| 1 | 3 | 0.3531 | 0.9867 | 2.1070 | 88.8000 | 388 | 31 |
| 1 | 4 | 0.3545 | 0.9822 | 2.1152 | 88.4000 | 389 | 33 |
| 1 | 5 | 0.3559 | 0.9822 | 2.1235 | 88.4000 | 390 | 33 |
| 1 | 6 | 0.3572 | 0.9822 | 2.1317 | 88.4000 | 391 | 33 |
| 1 | 7 | 0.3586 | 0.9822 | 2.1399 | 88.4000 | 392 | 33 |
| 1 | 8 | 0.3600 | 0.9822 | 2.1481 | 88.4000 | 393 | 33 |
| 1 | 9 | 0.3614 | 0.9822 | 2.1564 | 88.4000 | 394 | 33 |
| 2 | 1 | 0.0000 | 0.9356 | 0.0000 | 84.2000 | 132 | 54 |
| 2 | 2 | 0.1352 | 0.9356 | 0.8066 | 84.2000 | 230 | 54 |
| 2 | 3 | 0.1366 | 0.9356 | 0.8148 | 84.2000 | 231 | 54 |
| 2 | 4 | 0.1379 | 0.9333 | 0.8230 | 84.0000 | 232 | 55 |
| 2 | 5 | 0.1393 | 0.9244 | 0.8313 | 83.2000 | 233 | 59 |
| 2 | 6 | 0.1407 | 0.9178 | 0.8395 | 82.6000 | 234 | 62 |
| 2 | 7 | 0.1421 | 0.9178 | 0.8477 | 82.6000 | 235 | 62 |
| 2 | 8 | 0.1434 | 0.9111 | 0.8560 | 82.0000 | 236 | 65 |
| 2 | 9 | 0.1448 | 0.9022 | 0.8642 | 81.2000 | 237 | 69 |
| 2 | 10 | 0.1462 | 0.9022 | 0.8724 | 81.2000 | 238 | 69 |
| 2 | 11 | 0.1476 | 0.8933 | 0.8807 | 80.4000 | 239 | 73 |
| 3 | 1 | 0.0000 | 0.9356 | 0.0000 | 84.2000 | 132 | 54 |
| 3 | 2 | 0.1352 | 0.9356 | 0.8066 | 84.2000 | 230 | 54 |
| 3 | 3 | 0.1407 | 0.9089 | 0.8395 | 81.8000 | 234 | 66 |
| 3 | 4 | 0.1421 | 0.9044 | 0.8477 | 81.4000 | 235 | 68 |
| 3 | 5 | 0.1434 | 0.9022 | 0.8560 | 81.2000 | 236 | 69 |
| 3 | 6 | 0.3710 | 0.9778 | 2.2140 | 88.0000 | 401 | 35 |
| 3 | 7 | 0.3724 | 0.9778 | 2.2222 | 88.0000 | 402 | 35 |
| 3 | 8 | 0.3738 | 0.9778 | 2.2305 | 88.0000 | 403 | 35 |
| 3 | 9 | 0.3752 | 0.9778 | 2.2387 | 88.0000 | 404 | 35 |
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | quality_warning | 待验证 | 3 | 2026-07-23T17:07:34+00:00 |